Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 18, 2025 05:15 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
October 01, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM Receives Notice of Allowance for Composition-of-Matter Patent Covering FAP inhibitor-based Radiodiagnostics and Therapeutics in the United States

Basel, Switzerland / Munich, Germany, October 01, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that it...
September 24, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...
September 22, 2025 03:50 ET | Source: BetaGlue Therapeutics SpA

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer

BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
September 16, 2025 05:07 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...
September 16, 2025 05:00 ET | Source: NUCLIDIUM AG

NUCLIDIUM to Present Clinical Data from Phase I/II Study for Copper-based PET-Diagnostic in Neuroendocrine Tumors at EANM 2025

Basel, Switzerland / Munich, Germany, September 16, 2025 – NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced that...
September 08, 2025 11:05 ET | Source: Research and Markets

Brachytherapy Market Trends and Industry Outlook 2025-2030 - AI-Driven Dosimetric Modeling Offers Adaptive Treatment Plans, Projecting Optimal Outcomes Based on Historical Data

Dublin, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The "Brachytherapy Market Forecast 2025-2030" has been added to ResearchAndMarkets.com's offering. The Brachytherapy Market is set for significant...
September 04, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual...
August 19, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and...